T. Rowe Price Associates
TERN

T. Rowe Price Associates’s Terns Pharmaceuticals TERN Stock Holding History

T. Rowe Price Associates’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-634,496
Closed -$33.5M – 3332
2026
Q1 		$33.5M Sell
634,496
-339,816
-35% -$14M ﹤0.01% 899
2025
Q4 		$39.4M Buy
974,312
+880,139
+935% +$20.3M ﹤0.01% 880
2025
Q3 		$708K Buy
94,173
+14,605
+18% +$93.3K ﹤0.01% 2222
2025
Q2 		$297K Buy
79,568
+3,516
+5% +$11K ﹤0.01% 2537
2025
Q1 		$210K Sell
76,052
-1,428,186
-95% -$5.83M ﹤0.01% 2612
2024
Q4 		$8.34M Buy
1,504,238
+28,559
+2% +$193K ﹤0.01% 1182
2024
Q3 		$12.3M Buy
1,475,679
+1,448,996
+5,430% +$11.9M ﹤0.01% 1104
2024
Q2 		$182K Buy
26,683
+5,989
+29% +$36.3K ﹤0.01% 2613
2024
Q1 		$136K Buy
20,694
+2,261
+12% +$14.8K ﹤0.01% 2719
2023
Q4 		$120K Buy
18,433
+647
+4% +$3.42K ﹤0.01% 2688
2023
Q3 		$90K Buy
17,786
+800
+5% +$5.08K ﹤0.01% 2688
2023
Q2 		$149K Buy
+16,986
New +$198K ﹤0.01% 2608

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's TERN Position: Q2 2026 in Review

T. Rowe Price Associates sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 634,496 shares — an estimated $33.5M sold.

T. Rowe Price Associates first reported a position in TERN in Q2 2023 and held it in 12 quarters. The position peaked at $39.4M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • T. Rowe Price Associates reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 634,496 Terns Pharmaceuticals shares in Q2 2026, an estimated $33.5M.
  • T. Rowe Price Associates first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 12 quarters.
  • T. Rowe Price Associates's Terns Pharmaceuticals position peaked at $39.4M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.